Drug intelligence / Profile preview

DP-QB-MYA-002

Development stage: Phase 1
Lead developer: Alberta Health Services
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous

Overview

**DP-QB-MYA-002** is an investigational, in-vitro validated mycobacteriophage cocktail being developed by Alberta Health Services for chronic multidrug-resistant *Mycobacterium abscessus* subsp. *abscessus* pulmonary disease. It is being evaluated alongside conventional antimycobacterial agents with the intended goal of lowering pulmonary mycobacterial burden and improving respiratory outcomes. The individual phage constituents, bacterial receptors, manufacturing process, formulation, dose, and administration route have not been publicly disclosed.

Beyond the preview

Go deeper on DP-QB-MYA-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DP-QB-MYA-002.

Explore the full profile